KR20100133881A - 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법 - Google Patents

병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20100133881A
KR20100133881A KR1020097027516A KR20097027516A KR20100133881A KR 20100133881 A KR20100133881 A KR 20100133881A KR 1020097027516 A KR1020097027516 A KR 1020097027516A KR 20097027516 A KR20097027516 A KR 20097027516A KR 20100133881 A KR20100133881 A KR 20100133881A
Authority
KR
South Korea
Prior art keywords
leu
composition
robo4
gly
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097027516A
Other languages
English (en)
Korean (ko)
Inventor
딘 리
크리스토퍼 존스
니알 런던
Original Assignee
유니버시티 오브 유타 리써치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 유타 리써치 파운데이션 filed Critical 유니버시티 오브 유타 리써치 파운데이션
Publication of KR20100133881A publication Critical patent/KR20100133881A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
KR1020097027516A 2008-04-16 2009-04-16 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법 Withdrawn KR20100133881A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4558008P 2008-04-16 2008-04-16
US61/045,580 2008-04-16
US7388008P 2008-06-19 2008-06-19
US61/073,880 2008-06-19

Publications (1)

Publication Number Publication Date
KR20100133881A true KR20100133881A (ko) 2010-12-22

Family

ID=41199735

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097027516A Withdrawn KR20100133881A (ko) 2008-04-16 2009-04-16 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법

Country Status (8)

Country Link
US (1) US20100222401A1 (cg-RX-API-DMAC7.html)
EP (1) EP2262524A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011518178A (cg-RX-API-DMAC7.html)
KR (1) KR20100133881A (cg-RX-API-DMAC7.html)
CN (1) CN101687014A (cg-RX-API-DMAC7.html)
BR (1) BRPI0903901A2 (cg-RX-API-DMAC7.html)
CA (1) CA2693001A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009129408A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512327A (ja) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
US20110087603A1 (en) * 2009-10-13 2011-04-14 Google Inc. Cloud based media player and offline media access
US8620879B2 (en) * 2009-10-13 2013-12-31 Google Inc. Cloud based file storage service
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
US8399404B2 (en) 2010-06-15 2013-03-19 The Hospital For Sick Children Methods and uses for inhibiting platelet coagulation
US10561707B2 (en) * 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
EP3148986A4 (en) 2014-05-27 2018-01-10 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
RU2708375C2 (ru) * 2015-03-02 2019-12-06 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс Пептиды для ингибирования ангиогенеза
CN105726534A (zh) * 2016-02-17 2016-07-06 上海交通大学医学院附属仁济医院 SecinH3在制备抑制胃酸分泌药物中的应用
WO2017173327A1 (en) * 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
CN108929383B (zh) 2017-05-26 2021-10-15 阿思科力(苏州)生物科技有限公司 重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用
US11077422B2 (en) * 2017-06-16 2021-08-03 Aquablok, Ltd. Spalling composite particles and methods of using them
CN108364289B (zh) * 2018-03-02 2021-05-14 成都斯斐德科技有限公司 Ivoct图像易损斑块自动检测方法
CN108715862A (zh) * 2018-05-28 2018-10-30 上海海洋大学 ddx19基因缺失斑马鱼突变体的制备方法
GB2604482A (en) * 2019-10-18 2022-09-07 Emulate Inc Brain-chip modeling neurodegeneration and neuroinflammation in Parkinson's disease
JP7807617B2 (ja) 2020-03-14 2026-01-28 ヴァスキュラー・セラピューティクス・ピーティーワイ・エルティーディー 治療方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480975A (en) * 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US6372958B1 (en) * 1999-05-26 2002-04-16 The University Of Utah Research Foundation Transgenic mouse with endogenous endoglin gene disruption
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
WO2002010217A2 (en) * 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
US7939497B2 (en) * 2002-03-08 2011-05-10 Shanghai Institutes For Biological Sciences, Cas Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
WO2004003163A2 (en) * 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
DE102004055998A1 (de) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
DE102006054205A1 (de) * 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
JP2010512327A (ja) * 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
WO2010068917A2 (en) * 2008-12-12 2010-06-17 University Of Utah Research Foundation Compositions and methods for promoting vascular barrier function and treating pulmonary fibrosis

Also Published As

Publication number Publication date
BRPI0903901A2 (pt) 2017-05-23
JP2011518178A (ja) 2011-06-23
US20100222401A1 (en) 2010-09-02
CA2693001A1 (en) 2009-10-22
EP2262524A4 (en) 2012-07-11
WO2009129408A3 (en) 2009-12-23
CN101687014A (zh) 2010-03-31
EP2262524A2 (en) 2010-12-22
WO2009129408A2 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
US20100222401A1 (en) Compositions and methods for treating pathologic angiogenesis and vascular permeability
US7994130B2 (en) Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability
JP6975690B2 (ja) ヌトリン3aおよびペプチドを用いた肺線維症の阻害
US20070191273A1 (en) Modulation of angiogenesis
JP2019536813A (ja) Saspモジュレータおよび老化アテニュエータを含む組成物、ならびに細胞老化を調節するためのその使用
JP2021520845A (ja) マイクロペプチドとその使用
KR20110102142A (ko) 혈관 장벽 기능을 촉진하고 폐 섬유증을 치료하기 위한 조성물 및 방법
KR20230002817A (ko) 방법 및 조성물
WO2004064770A2 (en) Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney
CN103736092A (zh) 抑制新生淋巴管生成的方法和药物
JPWO2006134692A6 (ja) Ramp2を標的とする血管構造の安定化剤及び血管新生剤
JPWO2006134692A1 (ja) Ramp2を標的とする血管構造の安定化剤及び血管新生剤
US8080252B2 (en) Compounds and methods of modulating angiogenesis
CN106226531B (zh) Angpt2在筛选或制备用于诊断或治疗血管瘤的药物中的应用
WO2013056255A1 (en) Methods and compositions for inhibiting tumor cell proliferation
Grieshober The role of the N-fragment of Angiopoietin-like 4 during malignant melanoma metastasis formation
Stewart Characterising the in vitro and in vivo function of the RhoG effector DOCK4 during angiogenesis and ischemia.
EP2068877A2 (en) Compounds and methods of modulating angiogenesis
Ahmed Mechanistic Roles of Transforming Growth Factor-Beta and Receptor Tyrosine Kinase Cross-Talks in Sprouting Angiogenesis
Oas p120-catenin in vascular development and endothelial adhesion strengthening
Zhang et al. Phosphorylation dependent mitochondrial translocation of Nr4a3 provokes cardiomyocyte death
De Rossi A Study On The Roles And Effects Of Syndecans On Endothelial Cell Biology During Angiogenesis
Sewduth Characterisation de l’ubiquitine Ligase PDZRN3 en tant que nouvel acteur des voies Wnt dans la morphogenese et l’integrite vasculaire
Chatterjee The mechanism of regulation of fibroblast growth factor-2 (fgf-2) and vascular endothelial growth factor-a (vegf-a) dependent angiogenesis by junctional adhesion molecule-a (jam-a)
Nelson Activators of vinculin enhance cell adhesion and sensitize melanomas to chemotherapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091230

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid